Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia
Introduction: Flumatinib, a highly selective ABL kinase inhibitor, exhibits stronger inhibition of intracellular BCR-ABL tyrosine kinase activity, compared to Imatinib. However, there is limited research comparing the real-world efficacy and safety of flumatinib and dasatinib in patients with Philad...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-12-01
|
Series: | Hematology, Transfusion and Cell Therapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137924000130 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|